Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced and relapsed or refractory solid tumor or lymphoma
Protocol ID
MK-3475-051
Disease (Sub Disease)
Solid Tumour
Lymphoma
Lymphoma
Diagnosis Stage
Relapse/ refractory
Location
NSW, QLD, VIC
Sponsor
Merck Sharp & Dohme Corp.
Links
Trial Status
Open
Sites
The Children's Hospital at Westmead
Queensland Children's Hospital
Royal Children's Hospital
Sydney Children's Hospital
Royal Children's Hospital
Queensland Children's Hospital
Royal Children's Hospital
Sydney Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
6 months to 17 years
International registry ID's
NCT02332668
| Study Title | A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced and relapsed or refractory solid tumor or lymphoma |
|---|---|
| Protocol ID | MK-3475-051 |
| Disease (Sub Disease) | Solid Tumour Lymphoma |
| Diagnosis Stage | Relapse/ refractory |
| Location | NSW / QLD / VIC |
| Sponsor | Merck Sharp & Dohme Corp. |
| Links | https://clinicaltrials.gov/ct2/show/NCT02332668 |
| Trial Status | Open |
| Trial Open Date | 04/04/2016 |
| Sites | The Children's Hospital at Westmead / Queensland Children's Hospital/ Royal Children's Hospital / Sydney Children's Hospital / Royal Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 6 months to 17 years |
| International registry ID's | NCT02332668 |